Present and future treatment of pancreatic cancer

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 9, 2002, Pages 23-31

  Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LONAFARNIB; OXALIPLATIN; PEMETREXED; TRASTUZUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONFERENCE PAPER; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FUTUROLOGY; GROWTH INHIBITION; HUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR GROWTH;

EID: 0036314025     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.34269     Document Type: Conference Paper

References (60)

1. Gemcitabine: Progress in the treatment of pancreatic cancer
2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
3. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin
4. Efficacy of 5-FU + cisplatin (FUP) compared to bolus 5-FU (F) in advanced pancreatic carcinoma (APC): A randomized trial from the French Anticancer Centers Digestive Group (FNLCCDG)
5. A randomized trial of protracted venous infusion 5-fluorouracil with or without mitomycin-C in advanced pancreatic cancer
6. A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 (9566) in patients with advanced pancreatic cancer (APC)
7. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial
8. Interaction between cisplatin and gemcitabine in vitro and in vivo
9. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologico dell'italia
10. Weekly cisplatin (P) and gemcitabine (G) in patients with locally advanced or metastatic pancreatic cancer
11. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer
12. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma
13. Gemcitabine (G) and cisplatin (C) in the treatment of locally advanced and/or metastatic pancreatic carcinoma
14. Gemcitabine plus cisplatin vs. gemcitabine in advanced pancreatic cancer: Preliminary results of a randomized phase III trial
15. Cisplatin, gemcitabine, folinic acid, and fluorouracil in the treatment of locally advanced inoperable and/or metastatic pancreatic adenocarcinoma: A phase II study of the Southern Italian Oncology Group (GOIM)
16. Phase I-II trial of gemcitabine (GEM), continuous prolonged infusion of fluorouracil (FU) and cisplatin (CDDP) as treatment of patients with advanced pancreatic cancer (APC)
17. Gemcitabine, cisplatin and 5-fluorouracil in advanced cancer
18. Synergistic interaction of gemcitabine and 5-fluorouracil in colon cancer cells
19. A phase I/II clinical and pharmacologic study of dose-escalating and dose-sequencing administration of gemcitabine and folinic acid/ fluorouracil in advanced unresectable pancreatic cancer
20. Gemcitabine (GEM) alone or in combination with 5-FU continuous infusion (CI) in the treatment of advanced pancreatic cancer (APC): A GOIRC randomized phase II trial
21. A phase III study of gemcitabine in combination with 5-FU vs. gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): An Eastern Cooperative Oncology Group (ECOG) trial
22. Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma
23. A combination of gemcitabine (pharmacodynamically-based dose and schedule determined) and 5-fluorouracil in advanced pancreatic cancer. A GISCAD phase II study
24. Gemcitabine-oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma: A Gercor multicenter phase II study
25. A phase I/II study of gemcitabine (G) and docetaxel (D) in patients (Pts) with unresectable pancreatic cancer
26. Multi-center phase II trial of first-line irinotecan and gemcitabine (IrinoGem) in patients with locally advanced or metastatic pancreatic cancer
27. Front-line treatment of pancreatic carcinoma with gemcitabine (GMB) in combination with irinotecan (CPT-11): Preliminary results of a multicenter phase II study
28. Randomized phase II study of oxaliplatin alone (OXA), 5-fluorouracil (5FU) alone, and the two drugs combined (OXA-FU) in advanced or metastatic pancreatic adenocarcinoma (APC)
29. Phase II study of a combination with leucovorin (LV), 5 FU bolus and infusion (FU), gemcitabine (GEM) and oxaliplatin (L-OHP) (FOLFU GEMOX regimen) in locally advanced (LA) and metastatic (M) pancreatic carcinoma (APC)
30. Gemcitabine (GEM) and capecitabine (CPC) in advanced pancreatic cancer (APC) and solid tumors. A single institution experience
31. Combining gemcitabine (GEM) and capecitabine (CAP) in advanced pancreatic cancer. Results of a phase I trial
32. Phase II trial of Alimta plus Gemzar administered every 21 days in patients with advanced cancer
33. Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas
34. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody Cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer
35. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
36. Phase II trial of gemcitabine (2-2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
37. Phase II study of gemcitabine in patients with advanced pancreatic cancer
38. Treatment of advanced pancreatic cancer with gemcitabine as a single agent: A multicentre trial
39. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
40. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
41. Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic cancer
42. Docetaxel (D) with gemcitabine (GEM) in metastatic pancreatic cancer
43. Final results of a phase I study of weekly gemcitabine and docetaxel in pancreatic carcinoma and preliminary results of a phase II study
44. Docetaxel and gemcitabine in patients with advanced pancreatic cancer
45. Multicenter phase II study of weekly docetaxel and gemcitabine for the treatment of patients (pts) with advanced or recurrent pancreatic cancer
46. Pancreatic cancer: Biweekly gemcitabine/docetaxel chemotherapy
47. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: An Eastern Cooperative Oncology Group study (E3296)
48. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
49. Phase II trial with gemcitabine (GEM) + 5-fluorouracil (5-FU) in advanced pancreatic cancer (APC)
50. A phase II study of gemcitabine (GEM) plus 5-fluorouracil (5-FU) modulated by leucovorin (LV) for advanced pancreatic cancer
51. Preliminary results of a phase II study with gemcitabine and continuous infusion 5FU in patients with advanced or metastatic pancreatic cancer
52. Gemcitabine (Gem) and continuous infusional 5-FU (Cif) is active and well tolerated in advanced or metastatic pancreatic cancer
53. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer
54. Phase II study of gemcitabine (G) and continuous intravenous infusion (CIV) 5-fluorouracil (5-FU) in advanced pancreatic cancer: A University of Chicago Phase II Consortium study
55. Phase I-II study of gemcitabine (GEM) in combination with 24 hours continuous infusion (CI) of 5-fluorouracil (5-FU) and L-leucovorin (LV) in patients (Pts) with advanced pancreatic carcinoma (APC)
56. Phase II trial of gemcitabine (GEM) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) as first-line treatment for patients with locally advanced and metastatic exocrine pancreatic cancer (PC)
57. A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer
58. High-dose 5-fluorouracil (FU) 24-H-infusion with gemcitabine (GEM): Tolerable and efficient in palliative outpatient treatment of pancreatic cancer
59. Phase II study of gemcitabine (GEM) and weekly 48-hour continuous infusion (CI) high dose 5-fluorouracil (5-FU) in advanced exocrine pancreatic cancer
60. Multicenter phase II study in advanced pancreatic adenocarcinoma patients treated with a combination of leucovorin, 5-FU bolus and infusion, and gemcitabine (FOLFUGEM-regimen)